ClinicalTrials.gg

Program

GENSCI134

A development code. Also written as “GenSci134 Injection” and “GenSci134”.

Its studies are mostly in Dwarfism, Pituitary, led by Changchun GeneScience Pharmaceutical.

Furthest: phase 2, since Feb 12, 20263 company-led studies, 3 open or runningNext primary completion: Nov 25, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical33 open or runningphase 2since Feb 12, 2026May 30, 2025Nov 25, 2026phase 1 · NCT07016802

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 30, 2025First study: phase 1 study in Dwarfism, PituitaryFirst studyNCT07016802 · 64 planned · China
  2. Feb 12, 20262 phase 2 studiesPhase 2 reachedNCT07450053, NCT07450001

Ahead

  1. Nov 25, 2026Primary completion: phase 1 study in Dwarfism, PituitaryNCT07016802
  2. Jul 18, 2028Primary completion: phase 2 study in Idiopathic Short StatureNCT07450053
  3. Jul 18, 2028Primary completion: phase 2 study in Pediatric Growth Hormone DeficiencyNCT07450001

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07450053Idiopathic Short Stature · China2Not yet recruitingJul 18, 2028128
NCT07450001Pediatric Growth Hormone Deficiency · China2Not yet recruitingJul 18, 2028128
NCT07016802Dwarfism, Pituitary · China1RecruitingNov 25, 202664

How it is read

Names in the registry

  • “GenSci134 Injection”, 2 entries
  • “GenSci134”, 1 entry

Codes read as this program: GENSCI134.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.